Prevention/treatment of tardive dyskinesia.

Prevention/treatment of tardive dyskinesia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Prevention/treatment of tardive dyskinesia. Abstract Text:

J Gerlach,

Tardive dyskinesia (TD) is a syndrome of involuntary hyperkinetic movement associated with long-term neuroleptic treatment. The syndrome depends on 1. predisposing factors, especially high age and an unknown constitutional vulnerability, and 2. a postsynaptic dopamine receptor hypersensitivity and/or a cholinergic hypofunction developed during prolonged antidopaminergic (neuroleptic) treatment. TE is easily kept in check by continued and intensified neuroleptic treatment, which on the other hand presumably involves an aggravation of the underlying pathological process. On this account the importance of prevention can hardly be exaggerated. The most important prophylactic measures are: 1. narrowing the field of indications for the use of neuroleptics, 2. taking particular measures in predisposed subjects, 3. limiting the antidopaminergic influence by the use of neuroleptics with slight striatal antidopaminergic effect, lowest possible dose, shortest possible time of treatment, as well as increased intervals, and 4. paying close attention to the possible development of TD (early detection). The significance of anticholinergics is still not clarified. Apparently anticholinergics accentuate TD at the time of treatment, with contributing to the development of the underlying primary defect.

Prevention/treatment of tardive dyskinesia. Publishing Authors By Initials

J Gerlach,

For similar epidemiologic factors: sex factors research abstracts see: epidemiologic factors: sex factors research

PUBMED ID PMID:

MEDLINE DATE:

Prevention/treatment of tardive dyskinesia. Journal Published:

PUBLICATION TYPE: Review

Journal: Acta psychiatrica Scandinavica. Supplementum

VOLUME: 291

Page Numbers: 117-28

Journal Abbreviation:

ISSN: 0065-1591

DAY: 15

MONTH: 02

YEAR: 1981

Prevention/treatment of tardive dyskinesia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370365

Prevention/treatment of tardive dyskinesia. Keywords Mesh Terms:

KEYWORDS: Sex Factors

MESH TERMS: therapy

Chemical & Substance for Abstract: Prevention/treatment of tardive dyskinesia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Prevention/treatment of tardive dyskinesia.

AFFILIATION:

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Psychiatr Scand Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Prevention/treatment of tardive dyskinesia Related Publications

• An Actinobacillus pleuropneumoniae arcA deletion mutant is attenuated and deficient in biofilm formation.
• Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood.
• Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate.
• Characterization of a large transferrin-binding protein from Actinobacillus pleuropneumoniae serotype 7.
• Comparison of three common methods of lung lavage in healthy pigs.
• Continuing education: Innovation in tooth whitening: the science behind the smile part 1--fundamentals of whitening research.
• Evidence for increased oxidative stress in alcohol-dependent patients provided by quantification of in vivo salicylate hydroxylation products.
• Excimer laser channel creation in polyethersulfone hollow fibers for compartmentalized in vitro neuronal cell culture scaffolds.
• Oral versus depot administration of neuroleptics in relapse prevention.
• Prevention/treatment of tardive dyskinesia.
• Randomized controlled trial of professional at-home tooth whitening in teenagers.
• Respiratory disease markers in porcine bronchoalveolar lavage fluid.
• Silicate increases the release of MMP-9 forms in peripheral blood: why gelatin zymography differs significantly in citrate plasma and serum obtained with or without clot activators.
• Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report.
• Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis.
• [Chronic inflammatory liver diseases. Drug therapy]
• [Companionship for women dying of AIDS]
• [EXPERIENCES WITH CENTALUN IN OBSTETRICAL AND GYNECOLOGICAL PATIENTS.]
• [Effective iron therapy using a new concept]
• [Histopathological findings in drug addicts (author's transl)]
• [Identification and determination of age of needle tracks in human skin (author's transl)]
• [Initial action of synthetic sexual steroids on serum-haptoglobin concentration (author's transl)]
• [Intubation anesthesia in obstetrical and gynecological surgery. (Experiences based on 1078 cases in our own practice)]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Organic lesions after application of hashish in rats and rabbits (author's transl)]
• [Significance of ichthyol in gynecology]
• [The differentiation of gram-negative, anaerobic sporeless rods from the gut of various bird species]
• [Vinydan as a short-acting anesthetic in gynecology and its influence on liver function and enzyme activity]